Doha, December 4 (QNA) - The Precision Medicine and the Future of Genomics (PMFG) Summit 2025 concluded today after three days of events that highlighted three key transformative themes: artificial intelligence in genomics, clinical trials and real-world applications, and the application of precision medicine/population genomics and future prospects. This reflects a comprehensive approach to integrating research, technology, and clinical care into large-scale, population-level applications.

Jointly organized by Sidra Medicine and the Qatar Precision Healthcare Institute and sponsored by Qatar Foundation, the summit focused on Qatar's leadership in employing advanced genomics and artificial intelligence to study rare diseases.

Dr. Patrick Tan, a global leader in genomic medicine and AI-powered clinical diagnostics, emphasized in his keynote address on the final day the importance of sustained collaboration, data-driven innovation, and the adoption of advanced sequencing technologies to improve diagnostic pathways and patient outcomes, particularly for underserved populations.

A high-level panel of intellectuals discussed the future of integrating artificial intelligence, data-driven genomics, and global innovation at today's session. They emphasized the need to establish international reference datasets, develop research programs that represent diverse populations in the Middle East, and forge partnerships that enable the clinical application of these technologies.

Sidra's Executive Director of Translational Medicine, Dr. Sonia Davila and Executive Director of Research Facilities, Mohammed Ali Hameed - key participants in the PMFG Summit 2025- said that the goal of Summit is to foster global collaboration and increase investment in AI-powered diagnostic technologies, genomic data development, and clinical partnerships as fundamental pillars for advancing precision healthcare. Such partnerships have the potential to accelerate accurate diagnosis and reshape the future of clinical genomics, the explained

Head of Research at Sidra Medicine, Professor Khalid Fakhro said, "Sidra Medicine's mission to apply genomics and AI-enhanced diagnostics is an integral part of our collective efforts to improve care for children and families with rare diseases in Qatar and around the world." He added that this also aligns with Qatar's National Precision Medicine Strategy and reinforces its position as a center for advanced rare disease research and AI-driven genomic medicine.

On the third day of the summit, Sidra Medicine announced that its researchers had joined the international Hi-Fi Solves Alliance, a global consortium dedicated to advancing long-reading genomic sequencing technologies and eliminating the challenges of diagnosing rare diseases.

This alliance brings together leading experts in clinical genomics from around the world to accelerate the adoption of long-reading sequencing technologies in clinical settings, enhance data sharing, and promote their integration into healthcare systems.

This initiative aims to overcome current challenges in detecting structural variants, duplication expansions, and other complex genomic regions that are difficult to access using short-reading sequencing, while enabling multi-factor and AI-powered analyses to foster global collaboration and set a new standard in clinical genomics.

In this context, Head of the Population and Medical Genomics (MPG) Laboratory at Sidra Medicine, Professor Younes Mekrab stated that after ten years of working with long-read sequencing technologies, their full potential in revealing the underlying complexities of rare diseases is finally becoming clear. He added that by joining the Hi-Fi Solves Alliance, Sidra Medicine is contributing to a global initiative aimed at ensuring that communities in the Middle East gain access to the newest breakthroughs in precision medicine.

It is worth noting that Sidra Medicine researchers have been at the forefront of using long-reading sequencing in Qatar, a revolutionary technology that sequences large segments of DNA without fragmentation, achieving unprecedented accuracy and completeness.

Earlier this year, the MPG team received a significant grant from the Qatar Research, Development and Innovation Council to apply this technology to the treatment of rare neurological disorders in children in the Middle East.

For his part, Chair of the Hi-Fi Solves Alliance and Professor of Genomic Technologies and Immunogenetics at Radboud University Medical Center, Dr. Alexander Huischen explained that the Hi-Fi Solves Alliance represents the first worldwide initiative focused on fundamentally redefining how rare diseases are diagnosed. He noted that by bringing together top experts and cutting-edge long-read sequencing technologies, the alliance seeks to reduce the time it takes for patients to receive a diagnosis and to integrate advanced genomics more closely into clinical practice.

Sidra Medicine's participation in the Hi-Fi Solves initiative strengthens efforts to build national capacity in long-reading sequencing and multi-level sequencing research. This partnership builds on support and work previously funded by the Qatar Research, Development and Innovation Council and will contribute to establishing a regional benchmark for improving genome interpretation.

Sidra Medicine also announced that its Central Genomics Unit is now a PacBio-certified service provider, officially confirming that the center has met PacBio's standards for data quality, equipment performance, and staff expertise in long-reading sequencing. PacBio's Hi-Fi sequencing technology produces long, highly accurate DNA reads, enabling researchers to analyze parts of the genome that are difficult to study using other methods.

In turn, Associate Director of Advanced Research Units at Sidra Medicine, Dr. Sara Toumeh stated that earning the PacBio CSP certification demonstrates their strong dedication to excellence and to delivering top-quality services to the community. She added that as PacBio's Hi-Fi sequencing grows to encompass clinical and diagnostic uses, Sidra Medicine is proud to be well placed to contribute to the next wave of precision medicine advancements.

Sidra Medicine has consistently focused on advancing precision medicine, and in recent years has invested significant resources in its genomics capabilities, with PacBio technology playing a pivotal role in this development.

This certification underscores the quality of Sidra Medicine's sequencing services and reflects the institution's commitment to providing reliable, high-precision genomic support to researchers, clinicians, and the community at large. With the increasing adoption of hi-fi sequencing in applications such as structural variant detection and comprehensive genome analysis, Sidra Medicine is enhancing national and regional capacity to generate high-quality, long-term data and advance genomic research.

Sidra Medicine also announced significant milestones at its Innovation Lab, an initiative that serves as a gateway to the institution's clinical, scientific, and data capabilities. The lab is accessible to innovators, startups, and industry partners through a comprehensive innovation infrastructure, services, and integrated collaboration pathways.

The Innovation Lab provides access to clinical and research data, biological materials, and advanced genomic platforms. It also offers high-quality environments for verification and testing, including an industrial testing environment, structured pathways for co-development, intellectual property creation, clinical trials, commercialization, incubation space, and collaboration opportunities within Sidra Medicine's leading clinical and scientific ecosystem.

Through its Innovation Lab, Sidra Medicine aims to bridge the gap between research and real-world clinical applications, fostering collaboration to integrate innovative solutions into the healthcare system and bridging the gap between discovery and implementation. This will ensure that innovations translate into accessible care for all.

The summit concluded with an awards ceremony recognizing key partners, sponsors, and research collaborators who continue to support and contribute to the advancement of genomics and precision medicine in Qatar and the region. (QNA)